25.01
price down icon0.36%   -0.09
 
loading
前日終値:
$25.10
開ける:
$24.815
24時間の取引高:
1.21M
Relative Volume:
0.61
時価総額:
$140.82M
収益:
$90.12M
当期純損益:
$-276.06M
株価収益率:
-17.13
EPS:
-1.46
ネットキャッシュフロー:
$-193.47M
1週間 パフォーマンス:
+1.01%
1か月 パフォーマンス:
+161.88%
6か月 パフォーマンス:
+2,328%
1年 パフォーマンス:
+1,739%
1日の値動き範囲:
Value
$23.86
$26.29
1週間の範囲:
Value
$21.87
$26.29
52週間の値動き範囲:
Value
$0.432
$37.38

Nektar Therapeutics Stock (NKTR) Company Profile

Name
名前
Nektar Therapeutics
Name
セクター
Healthcare (1164)
Name
電話
(415) 482-5300
Name
住所
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Name
職員
61
Name
Twitter
@nektarnews
Name
次回の収益日
2025-03-12
Name
最新のSEC提出書
Name
NKTR's Discussions on Twitter

NKTR を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
NKTR
Nektar Therapeutics
25.01 140.82M 90.12M -276.06M -193.47M -1.46
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
468.85 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
567.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
314.94 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.24 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
250.30 28.51B 3.81B -644.79M -669.77M -6.24

Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-11 アップグレード Jefferies Hold → Buy
2025-03-14 アップグレード Oppenheimer Perform → Outperform
2025-01-08 開始されました B. Riley Securities Buy
2024-12-10 開始されました H.C. Wainwright Buy
2024-11-04 開始されました Piper Sandler Overweight
2024-09-30 再開されました BTIG Research Buy
2024-06-28 開始されました Rodman & Renshaw Buy
2023-11-20 再開されました JP Morgan Underweight
2023-11-09 アップグレード TD Cowen Market Perform → Outperform
2023-05-10 アップグレード Jefferies Underperform → Hold
2023-02-24 ダウングレード Jefferies Hold → Underperform
2022-08-08 ダウングレード JP Morgan Neutral → Underweight
2022-05-31 再開されました Jefferies Hold
2022-04-18 ダウングレード Goldman Neutral → Sell
2022-03-15 ダウングレード Cowen Outperform → Market Perform
2022-03-15 ダウングレード Mizuho Buy → Neutral
2022-03-14 ダウングレード BTIG Research Buy → Neutral
2022-03-14 ダウングレード BofA Securities Neutral → Underperform
2022-03-14 ダウングレード Stifel Buy → Hold
2022-03-14 ダウングレード William Blair Outperform → Mkt Perform
2022-03-09 アップグレード Oppenheimer Perform → Outperform
2021-11-08 アップグレード The Benchmark Company Hold → Buy
2021-09-10 開始されました BofA Securities Neutral
2021-06-28 アップグレード Stifel Hold → Buy
2021-05-18 再開されました Goldman Neutral
2021-02-22 ダウングレード The Benchmark Company Buy → Hold
2021-01-06 開始されました Stifel Hold
2020-09-14 開始されました JP Morgan Neutral
2020-06-10 ダウングレード CFRA Hold → Sell
2020-05-12 繰り返されました H.C. Wainwright Neutral
2020-04-22 開始されました The Benchmark Company Buy
2020-03-30 アップグレード Goldman Sell → Neutral
2020-03-04 開始されました Barclays Overweight
2020-02-03 アップグレード Mizuho Neutral → Buy
2019-10-24 開始されました Oppenheimer Perform
2019-10-08 ダウングレード Goldman Buy → Sell
2019-08-09 ダウングレード JP Morgan Overweight → Neutral
2019-08-09 ダウングレード Jefferies Buy → Hold
2019-08-09 ダウングレード Mizuho Buy → Neutral
2019-03-15 開始されました SVB Leerink Mkt Perform
2018-12-13 開始されました Goldman Buy
2018-06-11 ダウングレード H.C. Wainwright Buy → Neutral
2018-06-04 繰り返されました H.C. Wainwright Buy
2018-04-20 開始されました Seaport Global Securities Buy
2018-04-13 再開されました Piper Jaffray Overweight
2018-04-06 繰り返されました Mizuho Buy
2018-04-02 再開されました H.C. Wainwright Buy
すべてを表示

Nektar Therapeutics (NKTR) 最新ニュース

pulisher
Jun 16, 2025

Alopecia Areata Market Expected to Experience Major Growth by 2034, According to DelveInsight | Pfizer, Suzhou Zelgen Biopharma, Eli Lilly/ Incyte, Throne Biotech, Legacy Healthcare - Barchart.com

Jun 16, 2025
pulisher
Jun 11, 2025

Nektar Therapeutics: 2 Data Readouts For REZPEG 2025 Could Establish Further POC (NKTR) - Seeking Alpha

Jun 11, 2025
pulisher
Jun 11, 2025

Nektar Therapeutics (NASDAQ:NKTR) Shares Fly 29% But Investors Aren't Buying For Growth - simplywall.st

Jun 11, 2025
pulisher
Jun 08, 2025

Nektar therapeutics outlines REZOLVE-AD phase 2b data and financial position for Q2 2025 - MSN

Jun 08, 2025
pulisher
Jun 06, 2025

Nektar (NKTR) Trading Paused Ahead of Important Announcement | N - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Nektar Therapeutics Increases Authorized Shares To 390 Million - MarketScreener

Jun 06, 2025
pulisher
Jun 04, 2025

Nektar Therapeutics Approves Reverse Stock Split - TipRanks

Jun 04, 2025
pulisher
May 30, 2025

Millennium Management LLC Sells 536,773 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World

May 30, 2025
pulisher
May 29, 2025

Natural Killer (NK)-Cell Lymphoma Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

May 29, 2025
pulisher
May 29, 2025

D. E. Shaw & Co. Inc. Grows Stake in Nektar Therapeutics (NASDAQ:NKTR) - Defense World

May 29, 2025
pulisher
May 28, 2025

Metastatic renal cell carcinoma Pipeline 2025: Groundbreaking - openPR.com

May 28, 2025
pulisher
May 28, 2025

BNP Paribas Financial Markets Acquires 73,847 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World

May 28, 2025
pulisher
May 28, 2025

Nektar Therapeutics Elects New Board, Approves Key Proposals - TipRanks

May 28, 2025
pulisher
May 26, 2025

Natural Killer (NK)-Cell Lymphoma Market to Expand - openPR.com

May 26, 2025
pulisher
May 26, 2025

Natural Killer (NK)-Cell Lymphoma Market to Expand Significantly by 2032, States DelveInsight Report | Innate Pharma, Nektar Therapeutics, ImmunityBio, CytoVac, Celularity - The Globe and Mail

May 26, 2025
pulisher
May 23, 2025

Have Insiders Sold Nektar Therapeutics Shares Recently? - simplywall.st

May 23, 2025
pulisher
May 22, 2025

Nektar Therapeutics (NASDAQ:NKTR) Receives $4.50 Average Target Price from Analysts - Defense World

May 22, 2025
pulisher
May 20, 2025

Moderate to Severe Atopic Dermatitis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight - GlobeNewswire

May 20, 2025
pulisher
May 20, 2025

Nektar Therapeutics To Present At H.C. Wainwright BioConnect Conference; Webcast At 1:30 PM ET - Nasdaq

May 20, 2025
pulisher
May 16, 2025

Nektar Therapeutics (NASDAQ:NKTR) Rating Lowered to “Sell” at StockNews.com - Defense World

May 16, 2025
pulisher
May 16, 2025

What is William Blair’s Estimate for NKTR Q2 Earnings? - Defense World

May 16, 2025
pulisher
May 15, 2025

Nektar Therapeutics (NASDAQ:NKTR) Analysts Are More Bearish Than They Used To Be - simplywall.st

May 15, 2025
pulisher
May 15, 2025

Voya Investment Management LLC Acquires 121,187 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World

May 15, 2025
pulisher
May 15, 2025

Q2 EPS Estimate for Nektar Therapeutics Decreased by Analyst - Defense World

May 15, 2025
pulisher
May 14, 2025

GSK’s liver asset play grows group of $1B upfront deals - biocentury.com

May 14, 2025
pulisher
May 14, 2025

Nektar Therapeutics (NASDAQ:NKTR) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo Finance

May 14, 2025
pulisher
May 13, 2025

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference - Kilgore News Herald

May 13, 2025
pulisher
May 13, 2025

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd An - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down - MSN

May 13, 2025
pulisher
May 13, 2025

Time To Worry? Analysts Are Downgrading Their Nektar Therapeutics (NASDAQ:NKTR) Outlook - Yahoo Finance

May 13, 2025
pulisher
May 13, 2025

Nektar Therapeutics’ (NKTR) Market Perform Rating Reaffirmed at William Blair - Defense World

May 13, 2025
pulisher
May 12, 2025

Anticipated Clinical Trial Results and Financial Stability Justify Buy Rating for Nektar Therapeutics - TipRanks

May 12, 2025
pulisher
May 12, 2025

H.C. Wainwright maintains NKTR stock Buy rating, $6.50 target By Investing.com - Investing.com Nigeria

May 12, 2025
pulisher
May 12, 2025

H.C. Wainwright Reiterates Buy Rating on Nektar Therapeutics (NKTR) - StreetInsider

May 12, 2025
pulisher
May 12, 2025

Nektar Therapeutics (NASDAQ:NKTR) Stock Position Raised by Wells Fargo & Company MN - Defense World

May 12, 2025
pulisher
May 12, 2025

Barclays PLC Sells 32,476 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World

May 12, 2025
pulisher
May 12, 2025

Dendrimers And Polymer Drugs Conjugate Market to Witness - openPR.com

May 12, 2025
pulisher
May 12, 2025

H.C. Wainwright maintains NKTR stock Buy rating, $6.50 target - Investing.com

May 12, 2025
pulisher
May 11, 2025

Nektar Therapeutics (NASDAQ:NKTR) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st

May 11, 2025
pulisher
May 11, 2025

Nektar Therapeutics First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance

May 11, 2025
pulisher
May 11, 2025

Nektar Therapeutics (NASDAQ:NKTR) Q1 2025 Earnings Call Transcript - Insider Monkey

May 11, 2025
pulisher
May 09, 2025

Nektar Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks

May 09, 2025
pulisher
May 09, 2025

BTIG maintains Buy on Nektar stock, price target at $4.00 By Investing.com - Investing.com India

May 09, 2025
pulisher
May 09, 2025

Insiders Sold Nektar Therapeutics At US$1.06, Meanwhile Stock Sits Near US$0.62 - simplywall.st

May 09, 2025
pulisher
May 09, 2025

NEKTAR THERAPEUTICS SEC 10-Q Report - TradingView

May 09, 2025
pulisher
May 09, 2025

BTIG Reiterates Buy Rating on Nektar Therapeutics (NKTR) - StreetInsider

May 09, 2025
pulisher
May 09, 2025

Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ... By GuruFocus - Investing.com Canada

May 09, 2025
pulisher
May 09, 2025

Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ... - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and Financial Outlook - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Nektar Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 09, 2025
pulisher
May 09, 2025

Q1 EPS Estimates for Nektar Therapeutics Lowered by B. Riley - Defense World

May 09, 2025

Nektar Therapeutics (NKTR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Nektar Therapeutics (NKTR) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Wilson Mark Andrew
Chief Legal Officer
May 19 '25
Sale
0.67
9,996
6,697
314,296
ROBIN HOWARD W
President & CEO
May 19 '25
Sale
0.67
23,208
15,549
1,063,693
$21.40
price down icon 2.10%
$35.84
price down icon 0.78%
$25.00
price down icon 3.40%
$98.18
price up icon 1.57%
$112.89
price down icon 0.90%
biotechnology ONC
$250.30
price down icon 1.22%
大文字化:     |  ボリューム (24 時間):